Sector ratings Monte Rosa Therapeutics, Inc.
Stocks
GLUE
US61225M1027
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.38 USD | -6.90% |
|
-31.83% | -1.91% |
| 07-31 | Novo Nordisk Shares Sink After Heart Disease Drug Candidate Fails Late-Stage Trial | MT |
| 07-31 | Wedbush Adjusts Monte Rosa Therapeutics Price Target to $27 From $37, Maintains Outperform Rating | MT |
Main competitors
| Capi.($) | Investor | ESG MSCI | Fundamentals | Financial revisions | Global Valuation | Visibility | Consensus | ||
|---|---|---|---|---|---|---|---|---|---|
| 1.4B | - | B | - | - | |||||
| 48.53B | AAA | ||||||||
| 39.87B | - | B | - | - | |||||
| 38.68B | AAA | ||||||||
| 35.13B | - | ||||||||
| 29.79B | A | ||||||||
| 16.11B | BBB | ||||||||
| 16.08B | - | - | - | - | |||||
| 13.61B | AA | ||||||||
| 12.62B | AAA | ||||||||
| 11.23B | AA | ||||||||
| 11.2B | AA | ||||||||
| 10.54B | - | BBB | - | - | |||||
| 10.07B | - | B | - | - | |||||
| 9.09B | AA | ||||||||
| 8.79B | BB | - | |||||||
| 8.6B | - | A | - | - | |||||
| 8.58B | - | B | - | - | |||||
| 8.56B | AAA | ||||||||
| 8.51B | - | BBB | - | - | |||||
| Average | 17.35B | A | |||||||
| Weighted average by Cap. | A |
- Stock Market
- Stocks
- GLUE Stock
- Sector Monte Rosa Therapeutics, Inc.
- Sector ratings
Select your edition
All financial news and data tailored to specific country editions
















